Global Programmatic Survey on Governance and Surveillance of Nontuberculous Mycobacteria
Authors:
- Nityanand JainNityanand Jain
- Liga KuksaLKLiga Kuksa
- Dissou AffolabiDADissou Affolabi
- Fabiola Eliosa Arias MunozFMFabiola Eliosa Arias Munoz
- Sushil PandeySPSushil Pandey
- Lisa ShephardLSLisa Shephard
- Rumina HasanRHRumina Hasan
- Lorenzo GuglielmettiLGLorenzo Guglielmetti
- Gert-Jan WijnantGWGert-Jan Wijnant
- Emmanuel AndreEAEmmanuel Andre
- Leen RigoutsLRLeen Rigouts
Preprint
Abstract
Background: Nontuberculous mycobacteria (NTM) are clinically important pathogens but often weakly positioned within health systems, with unclear institutional ownership, variable notification arrangements, and limited surveillance visibility. Methods: We conducted a multilingual online survey among programme-facing national and subnational mycobacterial stakeholders from November to December 2025. Using an adaptive hierarchical recruitment strategy, we targeted 217 countries and jurisdictions. One response per programme was requested. We assessed institutionalisation, notification, agenda maturity, thematic discussion priorities, and barriers to action. We also derived relative policy momentum from three urgency domains (diagnostics, clinical management, and surveillance) using within-WHO region hierarchical clustering. Findings were used to develop a heuristic roadmap for staged NTM governance and system visibility. Results: We received 193 programme-level responses, including from subnational jurisdictions, representing 171 of 217 targeted countries (78.8% jurisdictional coverage). NTM institutionalisation status was heterogeneous: 34% reported NTM integration within the NTP, while 37% expressed intents to institutionalise within the NTP in nearest future. Mandatory notification was reported by 21% of programme units, voluntary notification by 10%, and notification under consideration by 24%. NTM appeared to enter policy discussions along a gradient, with clinical management and diagnostics attracting earlier attention than surveillance, training needs, and financing. Globally, pulmonary NTM was discussed more frequently than extrapulmonary disease. Across WHO regions, policy momentum clustering separated programmes into higher and lower profiles, with surveillance consistently being the weakest domain. Financing and lack of epidemiological data were identified as the most actionable barriers. There was broad support for TB-NTM surveillance integration. Conclusions: NTM governance is heterogeneous and frequently weakly anchored globally. The findings do not support a single universal institutional model; rather, existing mycobacterial platforms may provide pragmatic starting points for improving programme visibility, coordination, and reporting. The proposed heuristic roadmap outlines staged governance options according to burden, capacity, and institutional context.Keywords
This publication has 19 references indexed in Scilit:
- Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023The Lancet Infectious Diseases, 2025
- The potential impact of reductions in international donor funding on tuberculosis in low-income and middle-income countries: a modelling studyThe Lancet Global Health, 2025
- Global Epidemiology of Nontuberculous Mycobacterial Pulmonary DiseaseClinics in Chest Medicine, 2023
- Epidemiology of Pulmonary and Extrapulmonary Nontuberculous Mycobacteria Infections at 4 US Emerging Infections Program Sites: A 6-Month PilotClinical Infectious Diseases, 2023
- An analysis of existing national action plans for antimicrobial resistance—gaps and opportunities in strategies optimising antibiotic use in human populationsThe Lancet Global Health, 2023
- Environmental risk of nontuberculous mycobacterial infection: Strategies for advancing methodologyTuberculosis, 2023
- Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic reviewInternational Journal of Infectious Diseases, 2022
- Challenges of diagnosing and treating non-tuberculous mycobacterial pulmonary disease [NTM-PD]: A case seriesJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineClinical Infectious Diseases, 2020
- “Multidrug-resistant tuberculosis” may be nontuberculous mycobacteriaEuropean Journal of Internal Medicine, 2015